Increase in number of shares and votes in Vicore Pharma

2024-10-31 | Regulatory

Stockholm, October 31, 2024 – Vicore Pharma Holding AB (publ) (STO: VICO) (“Vicore”), a clinical-stage pharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the number of Vicore shares and votes has increased following (i) the rights issue of shares resolved by the Board of Directors on 10 September 2024, and registered with the Swedish Companies Registration Office on 14 October 2024, and (ii) the directed share issue resolved by the board of directors on 7 October 2024, and registered with the Swedish Companies Registration Office on 16 October 2024.

After the rights issue and the directed share issue, the total number of shares and votes in Vicore amounts to 234,579,119. The share capital has increased by SEK 61,422,556.903674 in total from SEK 55,867,001.45761 to SEK 117,289,558.361284.

For further information, please contact:
Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, megan.richards@vicorepharma.com
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma Holding AB
Vicore is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is advancing a portfolio of therapies in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) being investigated in a global Phase 2b trial in IPF. Almee™ is an investigational digital therapeutic in clinical development that is based on cognitive behavioral therapy and created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, which the Company believes reflects its potential to have transformative impact. Using its expertise in ATRAG chemistry and biology, Vicore is further developing its pipeline with several new therapies across additional indications. The company’s shares are listed on Nasdaq Stockholm’s main market (VICO). www.vicorepharma.com